COMP <GO>
ARVN vs CBIO // RSI-14 & 200D SMA MOMENTUM
Arvinas Inc. (NASDAQ) VS. Crescent Biopharma Inc. (NASDAQ) • 15-METRIC TALLY: ARVN 4
— CBIO 2
▲ RSI-14 & 200D SMA MOMENTUM LEADER: ARVN
LAST: $7.52 (-4.33%) • MKT CAP: $513.9M
rsi-technicals
54.4
LAST: $12.91 (-4.23%) • MKT CAP: $500.7M
rsi-technicals
46.5
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ARVN VS. CBIO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ARVN | CBIO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -32.10% | -35.00% | +2.90 | ARVN | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -13.86% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -45.10% | -60.00% | +14.90 | ARVN | /operating-margins <GO> |
| Net Profit Margin | -30.80% | 1.40% | -32.20 | CBIO | /net-margins <GO> |
| Revenue Growth (YoY) | -0.30% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 6.36 | -6.16 | CBIO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 3/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 54.4 | 46.5 | +7.90 | ARVN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $513.9M | $500.7M | $13.2M | ARVN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ARVN REV | CBIO REV | ARVN GROSS % | CBIO GROSS % | ARVN FCF | CBIO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $262.6M | $10.8M | — | — | -$275.7M | -$72.5M |
| FY 2024 | $263.4M | $112.1M | — | — | -$261.1M | -$31.1M |
| FY 2023 | $78.5M | $110.0M | — | — | -$347.8M | -$34.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ARVN // BETA —
CBIO // BETA —